Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin

Neurology ◽  
1988 ◽  
Vol 38 (2) ◽  
pp. 194-194 ◽  
Author(s):  
J.-Y. Delattre ◽  
B. Safai ◽  
J. B. Posner
1966 ◽  
Vol 4 (4) ◽  
pp. 13-13

Last month the US Food and Drug Administration required American manufacturers of long-acting sulphonamides (sulphamethoxypyridazine, Lederkyn - Lederle and Midicel - PD; sulphadimethoxine - Madribon - Roche) to warn prescribers that in rare cases the Stevens-Johnson syndrome may develop as a severe and sometimes fatal side effect. This syndrome is a type of erythema multiforme in which large blisters appear on the skin and especially on the mucous membranes. The manufacturers were also to advise doctors ‘to consider prescribing short-acting sulphonamides first because they are effective for most of the same conditions’. The three drug firms concerned accordingly sent a joint warning letter to all doctors, pointing out that the Stevens-Johnson syndrome is a serious complication with a mortality rate of about 25%. So far 116 cases of this syndrome have been reported in association with the use of long-acting sulphonamides, most of them in the United States. Almost two thirds of the patients were children.


1994 ◽  
Vol 111 (3P1) ◽  
pp. 236-242 ◽  
Author(s):  
Michael G. Stewart ◽  
Newton O. Duncan ◽  
Daniel J. Franklin ◽  
Ellen M. Friedman ◽  
Marcelle Sulek

Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis are related disorders of skin and mucous membranes, which are typically associated with antecedent medication use or infection. We review 108 cases of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis from Texas Children's Hospital, Houston, Texas, from 1981 to 1991, and illustrate the characteristic skin and mucosal lesions. In addition, we describe in detail two unusual cases requiring intensive airway management. Head and neck manifestations were present in 4 of 79 patients (5%) with erythema multiforme and 26 of 28 patients (93%) with Stevens-Johnson syndrome. In Stevens-Johnson syndrome, mucosal involvement of the lip (93%), conjunctiva (82%), oral cavity (79%), and nose (36%) were most common. Antecedent medication use was identified in 59% of erythema multiforme patients and 68% of Stevens-Johnson syndrome patients. We note a striking increase in the number of cases in our series caused by cephalosporins. Fifty percent of Stevens-Johnson syndrome patients required supplemental hydration or alimentation because of the severity of the oral cavity involvement. The head and neck mucosal manifestations largely respond to local care, and the routine use of prophylactic antibiotics or systemic steroids is not recommended.


2007 ◽  
Vol 25 (1) ◽  
pp. 27-30 ◽  
Author(s):  
Tadamasa Yoshitake ◽  
Katsumasa Nakamura ◽  
Yoshiyuki Shioyama ◽  
Tomonari Sasaki ◽  
Saiji Ooga ◽  
...  

1996 ◽  
Vol 17 (2) ◽  
pp. 63-64
Author(s):  
Daniel Rauch

Erythema multiforme (EM) is an acute hypersensitivity reaction characterized by distinctive skin lesions and mucous membrane involvement that has a spectrum of severity. It occurs in two forms: the more common "minor" type and the more severe "major" type, also called Stevens-Johnson syndrome (SJS). Sometimes EM includes toxic epidermal necrolysis (TEN) or Lyell disease. EM minor first was described completely by von Hebra in 1866; Stevens and Johnson described the major variant in 1922. EM occurs more often in males, and 20% to 50% of cases occur in the pediatric age group, although rarely in those younger than age 3 years.


Sign in / Sign up

Export Citation Format

Share Document